SAB Biotherapeutics (SABS) Capital Leases (2020 - 2026)

SAB Biotherapeutics has reported Capital Leases for 7 years, with the latest figure at $3.1 million in Q1 2026.

• For the quarter ending Q1 2026, Capital Leases fell 4.85% year-over-year to $3.1 million; the trailing twelve-month figure through Mar 2026 stood at $3.1 million (down 4.85% YoY), and the FY2025 full-year result was $3.1 million, down 4.7% from the prior year.
• Capital Leases for Q1 2026 stood at $3.1 million, down from $3.1 million in the prior quarter.
• The five-year high for Capital Leases was $3.7 million in Q1 2022, with the low at $3.1 million in Q1 2026.
• Historically, Capital Leases has averaged $3.4 million across 5 years, with a median of $3.4 million in 2024.
• Annual changes were most pronounced in 2022 — Capital Leases declined 3.53% — and 2024, when it retreated 5.9%.
• SAB Biotherapeutics' Capital Leases stood at $3.6 million in 2022, then fell by 5.82% to $3.4 million in 2023, then decreased by 4.17% to $3.3 million in 2024, then slipped by 4.7% to $3.1 million in 2025, then declined by 1.29% to $3.1 million in 2026.
• The last three Capital Leases figures came in at $3.1 million (Q1 2026), $3.1 million (Q4 2025), and $3.2 million (Q3 2025), per Business Quant data.